CHERIE BOOKER: Open Payments
NPI 1740309301 · REDDING, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,734 in 109 payments from 17 companies in 2025. Trend: 2023 $1,846 · 2024 $1,899 · 2025 $2,734
Food & beverage: $2,734
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $977 |
| Novo Nordisk Inc | 18 | $332 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $284 |
| Corcept Therapeutics | 8 | $220 |
| Lilly USA, LLC | 8 | $174 |
| Janssen Biotech, Inc. | 1 | $138 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $119 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $116 |
| Tandem Diabetes Care, Inc. | 5 | $72 |
| Phathom Pharmaceuticals, Inc. | 6 | $56 |
Products named: CREON, JARDIANCE, Rybelsus, Korlym, TREMFYA, Kerendia, XIFAXAN, Ozempic.
Industry payments across CA — which companies pay providers there.
